

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE US**

**Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing**

*Call Taking Place on Wednesday, October 14, 2020 @ 2pm Central European Time (CET)*

Schlieren (Zurich), Switzerland, October 1, 2020 – Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October 14, 2020 at 2pm Central European Time (CET).

The call will feature a presentation by Key Opinion Leaders John Chi, MD, MPH, Brigham and Women's Hospital, and Alpesh Patel, MD, Northwestern Medicine, who will discuss Kuros's products, Fibrin-PTH (KUR-113) and MagnetOs, which promote targeted and controlled bone healing. Drs. Patel and Chi will be available to answer questions at the conclusion of the call. Joost de Bruijn, Kuros's CEO, will also give a brief corporate update.

**This KOL event is restricted to participants outside the U.S., Australia and Japan.**

To [register](#) for the call, please click [here](#).

Kuros recently announced the treatment of the first patient in a Phase 2 clinical trial with Fibrin-PTH. Fibrin-PTH is the first-ever investigational drug-biologic product candidate being evaluated for spinal fusion and addresses a vast clinical need. Fibrin-PTH promotes controlled and targeted bone formation at the site of implantation and has been demonstrated in relevant animal models of spinal fusion to be comparable to rhBMP-2.

MagnetOs is an advanced bone graft commercialized in the U.S and the UK as an alternative to the gold standard treatment of autograft. Its unique submicron surface topography leads to the formation of bone instead of scar tissue in spinal fusion. MagnetOs has attained an osteoinductive claim in Europe, and its use is supported by a growing body of clinical data.

John Chi, MD, MPH is the Director of Neurosurgical Spinal Cancer in the Department of Neurosurgery and Associate Professor at Harvard Medical School and the coordinating PI of the phase 2 clinical trial with Fibrin-PTH. His clinical practice at Brigham and Women's Hospital is focused on personalizing comprehensive care for patients with spinal disorders and spinal tumors.

Dr. Chi has been at Harvard Medical School since 2008, prior to which he was Clinical Instructor at Johns Hopkins Hospital. Dr. Chi focuses on decompression, spinal fusion, and complex spinal reconstruction and is an expert at performing minimally invasive spine surgery. He holds an MD from Columbia University College of Physicians and Surgeons and was resident in neurosurgery at the University of California in San Francisco.

Alpesh Patel, MD is the Director of Orthopedic Spine Surgery at Northwestern Medical and a spine surgeon with fellowship training in both orthopedic spine surgery and neurosurgery. Dr. Patel specializes in cervical spine surgery and minimally invasive spine surgery. His experience and research include the areas of cervical spine surgery, cervical myelopathy, herniated discs, minimally invasive surgery, spine trauma and

spinal cord injuries. He is also known for his research in cost-effectiveness and value in spine care.

Dr. Patel is also Adjunct Associate Professor of Orthopedics at University of Utah Hospitals and Clinics and was previously at Loyola University Medical Center. He holds MDs from Northwestern, Washington University in St Louis and Thomas Jefferson University Hospitals.

**For further information, please contact:**

Kuros Biosciences AG  
Michael Grau  
Chief Financial Officer  
+41 44 733 47 47  
[michael.grau@kurosbio.com](mailto:michael.grau@kurosbio.com)

LifeSci Advisors  
Mary-Ann Chang  
Media & Investors  
+44 7483 284 853  
[mchang@lifesciadvisors.com](mailto:mchang@lifesciadvisors.com)

**About Kuros Biosciences AG**

*Kuros Biosciences is a leader in next generation synthetic bone graft technologies for targeted and controlled bone healing. Kuros's bone graft substitute, MagnetOs, is commercialized in the US and UK for use in posterolateral spinal fusions. Kuros's lead product in development, Fibrin PTH, a drug-biologic combination for spinal interbody fusion, is entering a phase 2 clinical trial in the U.S. Kuros is located in Schlieren (Zurich), Switzerland, Bilthoven, The Netherlands and Burlington (MA), U.S.A. The Company is listed on the SIX Swiss Exchange under the symbol KURN. Visit [www.kurosbio.com](http://www.kurosbio.com) for additional information on Kuros, its people, science and product pipeline.*

**About Fibrin-PTH (KUR-113)**

*Fibrin-PTH (KUR-113) consists of a natural fibrin-based healing matrix with an immobilized targeted bone growth factor (truncated human parathyroid hormone (PTH) analog). Fibrin-PTH (KUR-113) is designed to be applied directly into and around an intervertebral body fusion device as a gel, where it polymerizes in situ. Fibrin-PTH (KUR-113) functions via the well-established mechanism of action of parathyroid hormone; has been demonstrated in animal models of spinal fusion to be comparable to rhBMP-2; and has been shown in preclinical studies to be easy to use and ideal for open or minimally invasive techniques. The safety & efficacy of Fibrin PTH (KUR-113) has not yet been evaluated for spinal fusion in humans.*

**About MagnetOs**

*US indications statement*

*MagnetOs is an implant intended to fill bony voids or gaps of the skeletal system, i.e., posterolateral spine. MagnetOs must be used with autograft as a bone graft extender in the posterolateral spine. These osseous defects may be surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure.*

*EU indications statement*

*MagnetOs is intended for use as bone void filler for voids and gaps that are not intrinsic to the stability of the bony structure. MagnetOs is indicated for use in the treatment of surgically created osseous defects or osseous defects resulting from traumatic injury to the bone. MagnetOs is intended to be packed into bony voids or gaps of the skeletal system (i.e. extremities, spine, cranial, mandible, maxilla and pelvis) and may be combined with autogenous bone. MagnetOs should not be used to treat large defects that in the surgeon's opinion would fail to heal*

*spontaneously. In load bearing situations, MagnetOs is to be used in conjunction with internal or external fixation devices.*

**Forward Looking Statements**

*This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.*

*THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA. THIS DOCUMENT SHOULD IN PARTICULAR NOT BE DISTRIBUTED TO THE US-ADDRESSES OF UNITED STATES PERSONS OR TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. EVERY CONTRAVENTION OF THESE RESTRICTIONS MAY CONSTITUTE A BREACH OF THE RESPECTIVE SECURITIES LAWS OF THE COUNTRIES MENTIONED ABOVE.*